Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$4.55 +0.7%	$5.29	$4.06 ▼ $13.77	$543.07M	0.83	587,039 shs	393,358 shs
PGEN Precigen	$1.80 +3.4%	$1.53	$0.65 ▼ $2.17	$527.16M	1.57	2.04 million shs	1.13 million shs
SLN Silence Therapeutics	$3.91 -3.7%	$5.18	$3.90 ▼ $24.70	$117.03M	1.08	291,853 shs	148,821 shs
VERV Verve Therapeutics	$5.97 -2.9%	$6.99	$4.31 ▼ $14.30	$530.11M	1.77	1.43 million shs	676,140 shs

10 Best Stocks to Own in 2025

Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	-0.66%	-5.83%	-8.69%	-37.31%	-62.02%
PGEN Precigen	-2.25%	-6.95%	+2.35%	+157.66%	+14.47%
SLN Silence Therapeutics	-4.47%	-14.35%	-2.40%	-37.05%	-84.15%
VERV Verve Therapeutics	-4.21%	-6.96%	-21.25%	+7.71%	-57.11%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMTX Immatics	2.331 of 5 stars	3.6	2.0	0.0	3.4	1.7	0.0
PGEN Precigen	3.5526 of 5 stars	3.3	0.0	4.7	2.1	1.7	0.6
SLN Silence Therapeutics	2.6279 of 5 stars	3.4	4.0	0.0	1.9	1.7	0.6
VERV Verve Therapeutics	2.0079 of 5 stars	3.5	1.0	0.0	1.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMTX Immatics	3.20	Buy	$16.67	266.30% Upside
PGEN Precigen	2.60	Moderate Buy	$7.00	288.89% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$40.67	940.07% Upside
VERV Verve Therapeutics	3.00	Buy	$25.50	327.14% Upside

Current Analyst Ratings Breakdown

Latest SLN, IMTX, VERV, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/7/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/5/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$49.00 ➝ $45.00
3/4/2025	SLN Silence Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$67.00 ➝ $25.00
3/4/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$6.00 ➝ $4.00
3/4/2025	VERV Verve Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
2/28/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
2/21/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/11/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
1/29/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
1/23/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $6.00
1/14/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00

(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMTX Immatics	$115.50M	4.70	N/A	N/A	$2.88 per share	1.58
PGEN Precigen	$3.96M	133.02	N/A	N/A	$0.48 per share	3.75
SLN Silence Therapeutics	$43.26M	2.71	N/A	N/A	$0.71 per share	5.51
VERV Verve Therapeutics	$32.33M	16.40	N/A	N/A	$7.31 per share	0.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMTX Immatics	-$104.98M	-$0.66	N/A	N/A	N/A	-47.94%	-15.90%	-9.38%	3/20/2025 (Estimated)
PGEN Precigen	-$95.90M	-$0.55	N/A	N/A	N/A	-3,521.68%	-123.06%	-87.33%	3/18/2025 (Estimated)
SLN Silence Therapeutics	-$53.82M	-$0.83	N/A	N/A	N/A	-342.00%	-62.81%	-33.89%	5/15/2025 (Estimated)
VERV Verve Therapeutics	-$200.07M	-$2.35	N/A	N/A	N/A	-807.65%	-35.23%	-27.65%	5/14/2025 (Estimated)

Latest SLN, IMTX, VERV, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/20/2025	N/A	IMTX Immatics	-$0.03	N/A	N/A	N/A	$16.16 million	N/A
3/18/2025	N/A	PGEN Precigen	-$0.06	N/A	N/A	N/A	$1.30 million	N/A
2/27/2025	Q4 2024	VERV Verve Therapeutics	-$0.72	-$0.58	+$0.14	-$0.58	$3.94 million	$13.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMTX Immatics	N/A	3.98	3.98
PGEN Precigen	N/A	1.63	1.63
SLN Silence Therapeutics	N/A	9.31	9.31
VERV Verve Therapeutics	N/A	13.05	13.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMTX Immatics	64.41%
PGEN Precigen	33.51%
SLN Silence Therapeutics	98.73%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
IMTX Immatics	3.30%
PGEN Precigen	44.90%
SLN Silence Therapeutics	2.95%
VERV Verve Therapeutics	19.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMTX Immatics	260	119.36 million	115.42 million	Optionable
PGEN Precigen	190	292.87 million	161.37 million	Optionable
SLN Silence Therapeutics	100	29.93 million	N/A	Not Optionable
VERV Verve Therapeutics	110	88.80 million	68.32 million	Optionable

SLN, IMTX, VERV, and PGEN Headlines

Recent News About These Companies

Verve Therapeutics (NASDAQ:VERV) Stock Price Down 11% - What's Next?

March 11 at 3:04 PM | marketbeat.com

Mutated DNA Restored to Normal in Gene Therapy Advance

March 10, 2025 | nytimes.com

William Blair downgrades Neumora Therapeutics, Inc. (NMRA) to a Hold

March 7, 2025 | markets.businessinsider.com

Verve Therapeutics (NASDAQ:VERV) Shares Gap Down After Analyst Downgrade

March 6, 2025 | americanbankingnews.com

Royal Bank of Canada Lowers Verve Therapeutics (NASDAQ:VERV) Price Target to $15.00

March 6, 2025 | americanbankingnews.com

Verve Therapeutics (NASDAQ:VERV) Shares Gap Down on Analyst Downgrade

March 5, 2025 | marketbeat.com

Royal Bank of Canada Issues Pessimistic Forecast for Verve Therapeutics (NASDAQ:VERV) Stock Price

March 5, 2025 | marketbeat.com

Verve Therapeutics price target lowered to $15 from $17 at RBC Capital

March 4, 2025 | markets.businessinsider.com

What is William Blair's Estimate for VERV Q1 Earnings?

March 4, 2025 | americanbankingnews.com

Analysts Set Expectations for VERV Q1 Earnings

March 3, 2025 | marketbeat.com

Verve Therapeutics (NASDAQ:VERV) Stock Price Expected to Rise, HC Wainwright Analyst Says

March 1, 2025 | marketbeat.com

Verve is latest gene editing company to suffer setback, as Vertex walks away from pact

March 1, 2025 | endpts.com

Verve Therapeutics price target raised to $15 from $14 at H.C. Wainwright

March 1, 2025 | markets.businessinsider.com

Verve Therapeutics (NASDAQ:VERV) Releases Earnings Results, Beats Estimates By $0.14 EPS

February 28, 2025 | marketbeat.com

Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2

February 28, 2025 | seekingalpha.com

Verve Therapeutics Full Year 2024 Earnings: Beats Expectations

February 28, 2025 | finance.yahoo.com

Vertex ends gene editing research pact with Verve

February 27, 2025 | finance.yahoo.com

Vertex axes Verve gene editing pact amid shift in R&D priorities

February 27, 2025 | fiercebiotech.com

Vertex Severs Liver Gene Therapies Partnership with Verve

February 27, 2025 | biospace.com

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates

February 27, 2025 | zacks.com

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN, IMTX, VERV, and PGEN Company Descriptions

Immatics NASDAQ:IMTX

$4.55 +0.03 (+0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$4.55 0.00 (0.00%)

As of 04:05 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Precigen NASDAQ:PGEN

$1.80 +0.06 (+3.45%)

Closing price 04:00 PM Eastern

Extended Trading

$1.78 -0.02 (-0.83%)

As of 05:22 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Silence Therapeutics NASDAQ:SLN

$3.91 -0.15 (-3.69%)

Closing price 04:00 PM Eastern

Extended Trading

$3.98 +0.07 (+1.76%)

As of 05:37 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Verve Therapeutics NASDAQ:VERV

$5.97 -0.18 (-2.93%)

Closing price 04:00 PM Eastern

Extended Trading

$5.95 -0.02 (-0.34%)

As of 05:11 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time